New research published today in Blood Advances reveals that since the introduction of pneumococcal conjugate vaccines, PCV7 and PCV13, invasive pneumococcal infection (IPD) rates among children living ...

1 dose ≥8wks after last PCV dose 12 No additional vaccine 6 PCV15 or PCV20 1 dose ≥8wks after last pneumococcal vaccine 8 If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not ...

Eight PCV7-unimmunized children were age-matched to 28 immunized children. Four of the unimmunized children were each matched to 4 immunized children, and the remaining 4 unimmunized children were ...

"PCV use in infants clearly correlates with a substantial reduction in the prevalence of vaccine-type IPD among adults. However, IPD still represents a substantial burden of disease, and it is ...

The Centers for Disease Control and Prevention (CDC) now recommends that American adults over the age of 50 receive the pneumococcal conjugate vaccine, or PCV. The report with the updated ...

Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases. In the past month, PCVX's shares have nosedived 56%. This downside came after ...

Shares of Vaxcyte PCVX rose more than 36% on Tuesday after it reported positive top-line results from a phase I/II study on VAX-31, which is an investigational 31-valent pneumococcal conjugate vaccine ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...